The Efficacy of Neoadjuvant Chemotherapy for HER-2-Positive Locally Advanced Breast Cancer and Survival Analysis
Autor: | Huan Tian, Wei Zhang, Shi-hong Yang |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
0301 basic medicine
Oncology Adult Cancer Research medicine.medical_specialty Disease free survival Article Subject Receptor ErbB-2 medicine.medical_treatment Treatment outcome Locally advanced Breast Neoplasms Kaplan-Meier Estimate Disease-Free Survival Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine Humans Neoadjuvant therapy Survival analysis RC254-282 Aged Neoplasm Staging Aged 80 and over Chemotherapy QH573-671 business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Cell Biology General Medicine Middle Aged medicine.disease Survival Analysis Neoadjuvant Therapy 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Multivariate Analysis Clinical Study Molecular Medicine Neoplasm staging Female business Cytology |
Zdroj: | Analytical Cellular Pathology, Vol 2017 (2017) Analytical Cellular Pathology (Amsterdam) |
ISSN: | 2210-7185 2210-7177 |
Popis: | To provide reference data, we retrospectively investigated the effects of neoadjuvant chemotherapy (NAC) on 119 patients with HER-2+locally advanced breast cancer, treated from November 2010 to July 2016, with respect to influencing factors and survival. They were divided into the pathological complete response (pCR;n=15; 12.6%) and non-pCR (n=104; 87.4%) groups. We usedΧ2and logistic tests to the analyze effect and influencing factors. Survival rate was analyzed by the Kaplan-Meier method and Log-rank test. We lost 12 patients (including 1 pCR patient) and followed 107 patients, of whom 31 (all in the non-pCR group) had local recurrences or distant metastasis. The two groups significantly differed in 3-year disease-free survival (pCR group: 100%; non-pCR group: 59.0%;P=0.039); pCR was significantly affected by histological grade, PR status, Ki67 index, primary tumor size, clinical staging, and number of trastuzumab cycles. The model was tested, and the difference was statistically significant (Χ2 = 31.938,P=0.032). Patients with HER-2+locally advanced breast cancer with pCR responses to NAC have improved prognoses. Patients without pCR have increased risk for relapse. The use of a combination of NAC, such as trastuzumab and chemotherapy, and more cycles should be considered to increase the likelihood of pCR. |
Databáze: | OpenAIRE |
Externí odkaz: |